In cancers such as triple-negative breast cancer, ovarian cancer, clear cell renal carcinoma, glioblastoma, and low-grade lymphomas, IL4I1 expression levels correlate closely with tumor progression, clinical-pathological features, malignancy, and patient survival, making it a promising prognostic biomarker for various cancers [28,29,30,31,32]. This evidence concerns the gene IL4I1 and glioblastoma.